This story is just one example of the transformative possibilities that emerge when dedicated individuals and organizations unite to break down barriers in healthcare. Dr. Yehia and MRC team’s commitment to patient care and Eczacıbaşı-Monrol Nuclear Products contribution of Lutetium-177 doses underscore the collaborative success of the RLT-Platform, making a significant stride in accessible and advanced cancer care. We look forward to witnessing more stories of hope and make radiotheranostics options a reality. Join our efforts to increase the number of patients that can benefit from this life-saving technology.